Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis
Status:
Active, not recruiting
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This randomized phase III trial compares the effects, good and/or bad, of sorafenib tosylate
in treating patients with desmoid tumors or aggressive fibromatosis. Sorafenib tosylate may
stop the growth of tumor cells by blocking some of the proteins needed for cell growth.
[Funding Source - FDA OOPD]